Proton-pump inhibitor use amongst patients with severe hypomagnesemia
Frontiers in Pharmacology · 30.01.2023 · 14
DOI: 10.3389/fphar.2023.1092476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.01.2023. Verfasst von Sherry Seah und 20 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Long-term proton pump inhibitor (PPI) use has been associated with hypomagnesemia. It is unknown how frequently PPI use is implicated in patients with severe hypomagnesemia, and its clinical course or risk factors.
Methods
All patients with severe hypomagnesemia from 2013 to 2016 in a tertiary center were assessed for likelihood of PPI-related hypomagnesemia using Naranjo algorithm, and we described the clinical course. The clinical characteristics of each case of PPI-related severe hypomagnesemia was compared with three controls on long-term PPI without hypomagnesemia, to assess for risk factors of developing severe hypomagnesemia.
Results
Amongst 53,149 patients with serum magnesium measurements, 360 patients had severe hypomagnesemia (<0.4 mmol/L). 189 of 360 (52.5%) patients had at least possible PPI-related hypomagnesemia (128 possible, 59 probable, two definite). 49 of 189 (24.7%) patients had no other etiology for hypomagnesemia. PPI was stopped in 43 (22.8%) patients. Seventy (37.0%) patients had no indication for long-term PPI use. Hypomagnesemia resolved in most patients after supplementation, but recurrence was higher in patients who continued PPI, 69.7% versus 35.7%, p = 0.009. On multivariate analysis, risk factors for hypomagnesemia were female gender (OR 1.73; 95% CI: 1.17–2.57), diabetes mellitus (OR, 4.62; 95% CI: 3.05–7.00), low BMI (OR, 0.90; 95% CI: 0.86–0.94), high-dose PPI (OR, 1.96; 95% CI: 1.29–2.98), renal impairment (OR, 3.85; 95% CI: 2.58–5.75), and diuretic use (OR, 1.68; 95% CI: 1.09–2.61).
Conclusion
In patients with severe hypomagnesemia, clinicians should consider the possibility of PPI-related hypomagnesemia and re-examine the indication for continued PPI use, or consider a lower dose.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Doctor of Medicine Programme, Duke-NUS (National University School) Medical School, Singapore, Singapore.
- Department of Gastroenterology, Changi General Hospital, Singapore, Singapore.
- Department of Endocrinology, Changi General Hospital, Singapore, Singapore.
- Department of Clinical Trial Research Unit, Changi General Hospital, Singapore, Singapore.
- Department of Pharmacy, Changi General Hospital, Singapore, Singapore.
Zitieren
APA
Seah, S., Tan, Y. K., Teh, K., Loh, W. J., Tan, P. T., Goh, L. C., Malakar, R. D., Aw, T. C., Lau, C. S., Dhalliwal, T., Kui, S. L., Kam, J. W., Khoo, J., Tay, T. L., Tan, E., Au, V., Soh, S. B., Zhang, M., King, T. F., …, & Puar, T. H. (2023). Proton-pump inhibitor use amongst patients with severe hypomagnesemia. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1092476
Vancouver
Seah S, Tan YK, Teh K, Loh WJ, Tan PT, Goh LC, et al. Proton-pump inhibitor use amongst patients with severe hypomagnesemia. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1092476
BibTeX
@article{Seah2023,
author = {Seah, Sherry and Tan, Yen Kheng and Teh, Kevin and Loh, Wann Jia and Tan, Pei Ting and Goh, Leng Chuan and Malakar, Roy Debajyoti and Aw, Tar Choon and Lau, Chin Shern and Dhalliwal, Trishpal and Kui, Swee Leng and Kam, Jia Wen and Khoo, Joan and Tay, Tunn Lin and Tan, Eberta and Au, Vanessa and Soh, Shui Boon and Zhang, Meifen and King, Thomas F and Gani, Linsey and Puar, Troy H},
title = {Proton-pump inhibitor use amongst patients with severe hypomagnesemia},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1092476}
}
EUVIMED